Race Oncology Expands Vision Beyond Cancer With New Drug Discovery Program

Race Oncology expands vision beyond cancer with new drug discovery program

Proactive Investors

Race Oncology (ASX:RAC) Investor Briefing - Melbourne 20th Oct 2022

Investor Presentation

Race Oncology (ASX: RAC) reveals breakthrough chemotherapy heart protection discovery for Zantrene®

Race Oncology featured on NBN news

Race Oncology advances RNA epigenetics with FTO drug discovery at Monash

Proactive Investors

Race Oncology on RC220 ethics, 2024 milestones and 2025 outlook

Proactive Investors

Race Oncology starts world-first cancer trial to treat rare form of leukaemia

Race Oncology reports final data from preclinical melanoma research program

Proactive Investors

Race trials new Zantrene drug for Extramedullary Acute Myeloid Leukaemia (EMD AML) – Animation

Race Oncology AGM Nov 2022

Race Oncology (ASX: RAC) Day 2 of the IRD Invest 2021 conference.

Race Oncology (ASX: RAC) Investor briefing - May 2021

Race Oncology ASX Small and Mid Cap Conference

ASX

Race Oncology raises $29.7m to fund development of lead anti-cancer drug Zantrene

Race Oncology AGM 2021 CEO & CSO presentation with Share Purchase Program

Interview with Dr Ron Hargreaves - "The Early Development of Bisantrene"

Race Oncology poised for observational heart protection breast cancer trial

Proactive Investors